ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Monte Rosa launches to develop protein degraders

by Lisa M. Jarvis
May 29, 2020 | APPEARED IN VOLUME 98, ISSUE 21

 

Monte Rosa Therapeutics has launched with $32.5 million in funding from Versant Ventures and New Enterprise Associates. The Boston-based firm designs small molecules that modulate the activity of ubiquitin ligases, prompting unwanted proteins to be broken down. Monte Rosa, which was incubated in Versant’s Ridgeline laboratories, says it expects to begin clinical studies of one or more ubiquitin ligase–reprogramming drugs in 2021. It plans to raise its next round of funding soon to support the trials.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment